

| Type of survey | Number of respondents | Average burden/response | Total hours of burden |
|----------------|-----------------------|-------------------------|-----------------------|
| Totals | 103,400 | NA | 16,356 |

Request for Comments

In accordance with the above cited Paperwork Reduction Act legislation, comments on the AHRQ's information collection are requested with regard to any of the following: (a) Whether the proposed collection of information is necessary for the proper performance of functions of AHRQ, including whether the information will have practical utility; (b) the accuracy of the Agency's estimate of the burden (including hours and costs) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Dated: July 6, 2004.

Carolyn M. Clancy,
Director.

[FR Doc. 04-15786 Filed 7-12-04; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Request for Applications To Determine the Pharmacokinetics of Clostridium Botulinum Neurotoxins A, B, C, E, and F, Program Announcement Number 04099

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting: Request for Applications To Determine the Pharmacokinetics of Clostridium Botulinum Neurotoxins A, B, C, E, and F, Program Announcement Number 04099.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Request for Applications to

Determine the Pharmacokinetics of Clostridium Botulinum Neurotoxins A, B, C, E, and F, Program Announcement Number 04099.

Times and Dates: 1 p.m.-1:30 p.m., July 29, 2004 (open); 1:30 p.m.-3:30 p.m., July 29, 2004 (closed).

Place: Teleconference number 1-877-951-9728, pass code 362242.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement Number 04099.

Contact Person for More Information: Trudy Messmer, Ph.D., Scientific Review Administrator, National Center for Infectious Diseases, CDC, 1600 Clifton Road, NE., MS-C19, Atlanta, GA 30333, telephone (404) 639-37706.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 7, 2004.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04-15792 Filed 7-12-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control; Special Emphasis Panel (SEP): Monitoring Atypical HIV Strains Among Persons Newly Diagnosed With HIV Using Blood Spots vs. Diagnostic Sera, Program Announcement Number 04118

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Monitoring Atypical HIV Strains

Among Persons Newly Diagnosed with HIV Using Blood Spots vs. Diagnostic Sera, Program Announcement Number 04118.

Times and Dates: 8:30 a.m.-9:15 a.m., August 3, 2004 (open), 9:15 a.m.-4:15 p.m., August 3, 2004 (closed).

Place: The Westin Buckhead Atlanta, 3391 Peachtree Road, NE., Atlanta, GA 30326, Telephone Number (404) 365-0065.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Special Emphasis Panel (SEP): Monitoring Atypical HIV Strains Among Persons Newly Diagnosed with HIV Using Blood Spots vs. Diagnostic Sera, Program Announcement Number 04118.

For Further Information Contact: Noreen L. Qualls, DrPH, Scientific Review Administrator, Centers for Disease Control, National Center for HIV, STD, Office of the Associate Director for Science, 1600 Clifton Road NE., Mailstop E07, Atlanta, GA 30333, Telephone (404) 639-8006.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 29, 2004.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04-15795 Filed 7-12-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Research Into the Public Health Aspects of West Nile Virus in the United States, PA #04052

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Research into the Public Health

Aspects of West Nile Virus in the United States, PA #04052.

Times and Dates: 8:30 a.m.–9 a.m., August 2, 2004 (Open). 9:15 a.m.–6 p.m., August 2, 2004 (Closed). 8:30 a.m.–9 a.m., August 3, 2004 (Open). 9:15 a.m.–6 p.m., August 3, 2004 (Closed).

Place: Renaissance Concourse Hotel, One Hartsfield Centre Parkway, Atlanta, GA 30354, Telephone (404) 209-9999.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to: Research into the Public Health Aspects of West Nile Virus in the United States, PA #04052.

For Further Information Contact: Trudy Messmer, Ph.D., Scientific Review Administrator, Centers for Disease Control, National Center for Infectious Diseases, 1600 Clifton Road NE., Mailstop C19, Atlanta, GA 30333, Telephone (404) 639-2176.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 1, 2004.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04-15800 Filed 7-12-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Initial Discussions for Concepts of Total Inward Leakage (TIL) Requirements and Test Methods for Halfmask Respirators Including Elastomeric and Filtering Facepiece Styles.

Date and Time: 9 a.m.–5 p.m., August 25, 2004.

Place: Marriott Key Bridge Hotel located at 1401 Lee Highway, Arlington, Virginia.

Status: This meeting is hosted by NIOSH and will be open to the public, limited only by the space available. The meeting room will accommodate approximately 50 people. Sleeping Rooms are reserved under a NIOSH/ National Personal Protective Technology

Laboratory (NPPTL) Public Meeting room block for the evening of Tuesday, August 24, 2004, at the government rate of \$150 per night. The NIOSH/NPPTL public meeting must be referenced to receive this special rate. Interested parties should make hotel reservations directly with the Marriott at 1-800-228-9290 or 703/524-6400 before the cut-off date of August 4, 2004. Interested parties should confirm their attendance to this meeting by completing a registration form and forwarding it by e-mail (npptlevents@cdc.gov) or fax (304-285-4459) to the NPPTL Event Management Office. A registration form may be obtained from the NIOSH Homepage (www.cdc.gov/niosh) by selecting conferences and then the event.

An opportunity to make presentations regarding the discussions of concepts for standards and testing processes for TIL requirements and test methods suitable for halfmask respirators will be given. Requests to make such presentations at the public meeting should be made by e-mail or the NPPTL Event Management Office (npptlevents@cdc.gov). All requests to present should include the name, address, telephone number, relevant business affiliations of the presenter, a brief summary of the presentation, and the approximate time requested for the presentation. Oral presentations should be limited to 15 minutes.

After reviewing the requests for presentations, NPPTL Event Management will notify each presenter of the approximate time that their presentation is scheduled to begin. If a participant is not present when their presentation is scheduled to begin, the remaining participants will be heard in order. At the conclusion of the meeting, an attempt will be made to allow presentations by any scheduled participants who missed their assigned times. Attendees who wish to speak but did not submit a request for the opportunity to make a presentation may be given this opportunity at the conclusion of the meeting, at the discretion of the presiding officer.

Comments on the topics presented in this notice and at the meeting should be mailed to the NIOSH Docket Office, Robert A. Taft Laboratories, M/S C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226, Telephone 513-533-8303, Fax 513-533-8285. Comments may also be submitted by e-mail to niocindocket@cdc.gov. E-mail attachments should be formatted in Microsoft Word. Comments should be submitted to Niosh no later than September 25, 2004, and should reference Docket Number NIOSH\036 in the subject heading.

Purpose: NIOSH will initiate discussions of conceptual standards and testing processes for TIL requirements and test methods suitable for halfmask respirators. NIOSH also wishes to obtain comments from individuals regarding the tentative schedules and priorities for future TIL respirator and other personal protective equipment standards development efforts. NIOSH will present information to attendees concerning the concept development for the overall TIL program and the initial concept for TIL testing for halfmask respirator testing and certification requirements. Participants will

be given an opportunity to ask questions on these topics and to present individual comments for consideration. Interested participants may obtain a copy of the TIL concept paper from the NIOSH NPPTL web site, address: www.cdc.gov/niosh/npptl. The April 20, 2004, concept paper will be used as the basis for discussion at the public meeting. NIOSH wishes to obtain comments from individuals regarding the priorities for future standards efforts following the completion of the halfmask TIL standard.

For Further Information Contact: NPPTL Event Management, 3610 Collins Ferry Road, P.O. Box 880, Morgantown, West Virginia 26507-0880, Telephone 304-285-4750, Fax 304-285-4459, E-mail npptlevents@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 7, 2004.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04-15799 Filed 7-12-04; 8:45 am]

BILLING CODE 4163-19-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003E-0247]

Determination of Regulatory Review Period for Purposes of Patent Extension; CAMPATH

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for CAMPATH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.

ADDRESSES: Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda/dockets/ecomments>.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Office of Regulatory Policy (HFD-013), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 240-453-6699.